STOCKWATCH: Venture capital sees new signs of life as IPOs, M&A create value
This article was originally published in Scrip
Executive Summary
Was it the usual year-end burst of investment activity or was the fourth quarter spike in US biotechnology venture capital investment spurred by 2013's vigorous market for initial public offerings and high-value mergers and acquisitions?